Brand Name | Status | Last Update |
---|---|---|
buphenyl | New Drug Application | 2024-10-30 |
olpruva | New Drug Application | 2024-12-18 |
pheburane | New Drug Application | 2024-12-20 |
ravicti | New Drug Application | 2021-09-13 |
sodium phenylbutyrate | ANDA | 2024-07-10 |
Expiration | Code | ||
---|---|---|---|
SODIUM PHENYLBUTYRATE / TAURURSODIOL, RELYVRIO, AMYLYX | |||
2029-09-29 | ODE-411 | ||
2027-09-29 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Inborn errors lipid metabolism | D008052 | — | — | — | 1 | — | — | — | 1 |
Multiple acyl coenzyme a dehydrogenase deficiency | D054069 | — | E71.313 | — | 1 | — | — | — | 1 |
Drug common name | Sodium phenylbutyrate |
INN | — |
Description | Sodium phenylbutyrate is the organic sodium salt of 4-phenylbutyric acid. A prodrug for phenylacetate, it is used to treat urea cycle disorders. It has a role as a prodrug, an EC 3.5.1.98 (histone deacetylase) inhibitor, a neuroprotective agent, an orphan drug and a geroprotector. It contains a 4-phenylbutyrate. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C([O-])CCCc1ccccc1.[Na+] |
PDB | — |
CAS-ID | 1716-12-7 |
RxCUI | — |
ChEMBL ID | CHEMBL1746 |
ChEBI ID | 75316 |
PubChem CID | 5258 |
DrugBank | DBSALT002404 |
UNII ID | — |